Response to Letter to the Editor: "Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes"

J Clin Endocrinol Metab. 2020 Jun 1;105(6):e2317-e2318. doi: 10.1210/clinem/dgaa144.

Venessa H M Tsang^{1

2

3}, Rachel T McGrath^{1

2}, Roderick J Clifton-Bligh^{1

2

3}, Richard A Scolyer^{4

5}, Valerie Jakrot⁴, Alexander D Guminski^{4

6}, Georgina V Long^{4

6}, Alexander M Menzies^{4

6}

¹ Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, St Leonards Sydney, Australia.
² Sydney Medical School, Northern, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
³ Cancer Genetics Laboratory, Hormones and Cancer Group, Kolling Institute of Medical Research, Sydney, NSW, Australia.
⁴ Melanoma Institute Australia and The University of Sydney, Sydney, Australia.
⁵ Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
⁶ Departments of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.

No abstract available

Publication types